Addressees
Registrant(s) of 996-35-0_JS as listed in the last Appendix of this decision

Date of submission for the jointly submitted dossier subject to this decision
27/05/2021

Registered substance subject to this decision ("the Substance")
Substance name: N,N-dimethylisopropylamine
EC number: 213-635-5

Decision number: Please refer to the REACH-IT message which delivered this communication (in format CCH-D-XXXXXXXXXX-XX-XX/F)

DECISION TAKEN UNDER ARTICLE 42(1) OF THE REACH REGULATION

By the decision of 23 November 2018 ("the original decision") ECHA requested you to submit information by 31 May 2021 in an update of your registration dossier.

Based on Article 42(1) of Regulation (EC) No 1907/2006 (the ‘REACH Regulation’), ECHA examined the information you submitted with the registration dossier specified in the header above, and concludes that

Your registration still does not comply with the following information requirement(s):

A. Information required from all the Registrants subject to Annex VIII of REACH
   1. Screening for reproductive/developmental toxicity (Annex VIII, Section 8.7.1.; test method: OECD 421/422) in rats, oral route with the registered substance;

B. Information required from all the Registrants subject to Annex IX of REACH
   1. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method: OECD TG 414) in a first species (rat or rabbit), oral route with the registered substance.

You are therefore still required to provide this information requested in the original decision.

Reasons for the request(s) are explained in the following appendices:

- Appendix entitled "Reasons common to several requests";
- Appendices entitled “Reasons to request information required under Annexes VIII to IX of REACH”, respectively.

Appeal
This decision, when adopted under Article 51 of REACH, may be appealed to the Board of Appeal of ECHA within three months of its notification to you. Please refer to http://echa.europa.eu/regulations/appeals for further information.
Failure to comply

The respective Member State competent authority (MSCA) and National enforcement authority (NEA) will be informed of this decision. They have the duty under Articles 125 and 126 of Regulation No 1907/2006 to ensure that the requests in the original decision are enforced and complied with and, to that end, inter alia, to carry out checks and impose effective, proportionate and dissuasive penalties1.

Authorised2 under the authority of Mike Rasenberg, Director of Hazard Assessment

---

1 See paragraph 143 of the judgment of the European Court of Justice of 21 January 2021 in Case C-471/18 P Germany v Esso Raffinage.

2 As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA’s internal decision-approval process.
Appendix on Reasons common to several requests

1. Assessment of your read-across approach under Annex XI, Section 1.5.

i. Assessment of the Grouping of substances and read-across approach under Annex XI, Section 1.5.

You seek to adapt the following standard information requirements by applying (a) read-across approach(es) in accordance with Annex XI, Section 1.5:

- Screening for reproductive/developmental toxicity (Annex VIII, Section 8.7.1.)
- Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.)

ECHA has considered the scientific and regulatory validity of your read-across approach(es) in general before assessing the specific standard information requirements in the following appendices.

Grouping of substances and read-across approach

Annex XI, Section 1.5. specifies two conditions which must be fulfilled whenever a read-across approach is used. Firstly, there needs to be structural similarity between substances which results in a likelihood that the substances have similar physicochemical, toxicological and ecotoxicological properties so that the substances may be considered as a group or category. Secondly, it is required that the relevant properties of a substance within the group may be predicted from data for reference substance(s) within the group (addressed under ‘Assessment of prediction(s)’).

Additional information on what is necessary when justifying a read-across approach can be found in the ECHA Guidance R.6. and related documents.\(^3\),\(^4\).

A. Predictions for toxicological properties

You have provided a read-across justification document in IUCLID Section 7.8.2.

You read-across between the structurally similar substances, N,N-Dimethylethylamine (DMEA), EC No. 209-940-8, and Ethyldiisopropylamine (EDIPA), EC No. 230-392-0, as source substances and the Substance as target substance.

You have provided the following reasoning for the prediction of toxicological properties:

“the three above substances were identified as potential suitable analogues based on structural similarities, physicochemical properties and therefore a read across approach may be applied providing that the toxicological requested studies that will be generated with EDIPA, DMIPA, and DMEA will demonstrate comparable toxicological profiles.”

ECHA understands that you predict the properties of the Substance using a read-across hypothesis which assumes that different compounds have the same type of effects. The properties of your Substance are predicted to be quantitatively equal to those of the source substance.

ECHA notes the following shortcoming(s) with regards to prediction(s) of toxicological properties:

---


\(^4\) Read-across assessment framework (RAAF) - considerations on multi-constituent substances and UVCBs. 2017 (March) ECHA, Helsinki. 40 pp. Available online: https://doi.org/10.2823/794394
properties.

**Supporting information**

Annex XI, Section 1.5 of the REACH Regulation states that “physicochemical properties, human health effects and environmental effects or environmental fate may be predicted from data for reference substance(s)”. For this purpose “it is important to provide supporting information to strengthen the rationale for the read-across” (Guidance on IRs and CSA R.6, Section R.6.2.2.1.f.). The set of supporting information should allow to verify the crucial aspects of the read-across hypothesis and establish that the properties of the Substance can be predicted from the data on the source substance(s).

Supporting information must include bridging studies to compare properties of the Substance and source substances.

As indicated above, your read-across hypothesis is based on the assumption that the structurally similar substances cause the same type of effect(s). In this context, relevant, reliable and adequate information allowing to compare the properties of the Substance and of the source substance(s) is necessary to confirm that both substances cause the same type of effects. Such information can be obtained, for example, from bridging studies of comparable design and duration for the Substance and of the source substance(s).

For the Substance, you provided an OECD TG 412 study (2021) for repeated dose toxicity. However, your registration dossier does not include any robust study summaries or descriptions of data for the Substance addressing reproductive performance or developmental toxicity that would confirm that the Substance and the source substances cause the same type of effects for these properties.

In the absence of such information, you have not established that the Substance and the source substance(s) are likely to have similar properties. Therefore you have not provided sufficient supporting information to strengthen the rationale for the read-across.

As further explained in Appendix A, section 1 and Appendix B, section 1 below, you propose in your comments to the draft decision a step by step testing strategy in order to confirm if the read-across is applicable and the category confirmed.

**B. Conclusions on the read-across approach**

As explained above, you have not established that relevant properties of the Substance can be predicted from data on the analogue substance. Therefore, your adaptation does not comply with the general rules of adaptation as set out in Annex XI, Section 1.5. and your grouping and read-across approach is rejected.
Appendix A: Reasons to request information required under Annex VIII of REACH

1. Screening for reproductive/developmental toxicity

You were requested to submit information derived with the registered substance for screening for reproductive/developmental toxicity.

In response, you provided a screening for reproductive / developmental toxicity (2021) with N,N-Dimethylethylamine (DMEA), EC No. 209-940-8.

We have reviewed this information and identified the following issue(s):

As explained in the Appendix entitled “Reasons common to several requests” your adaptation according to Annex XI Section 1.5. is still rejected.

In your comments to the draft decision you explain that you will perform an OECD TG 421 study with the aim of strengthening the category approach.

Based on the above, the information you provided does not fulfil the information requirement and you are still required to provide Screening for reproductive/developmental toxicity (Annex VIII, Section 8.7.1.; test method: OECD 421/422) in rats, oral route with the registered Substance.
Appendix B: Reasons to request information required under Annex IX of REACH

1. Pre-natal developmental toxicity study in one species

You were requested to submit information derived with the registered substance for pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method: OECD TG 414) in a first species (rat or rabbit), oral route with the registered substance.

In response, you provided one pre-natal developmental toxicity study with N,N-Dimethylethylamine (DMEA), EC No. 209-940-8 (2020) and one pre-natal developmental toxicity study with Ethylidisopropylamine (EDIPA), EC No. 230-392-0 (2021).

We have reviewed this information and identified the following issue(s):

As explained in the Appendix entitled “Reasons common to several requests” your adaptation according to Annex XI Section 1.5. is still rejected.

In your comments to the draft decision you explain that if the results of the OECD TG 421 support the category there will be no need for an OECD 414 study. Therefore you ask ECHA to postpone the request for the OECD 414.

ECHA acknowledges the approach you describe in your comments but has no discretion to “postpone” the request for an OECD TG 414 study as currently your registration dossier does not comply with the information requirement under Annex IX, Section 8.7.2.

ECHA will evaluate your dossier when the new information has been submitted in a dossier update.

Based on the above, the information you provided does not fulfil the information requirement and you are still required to provide Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method: OECD TG 414) in a first species (rat or rabbit), oral route with the registered substance.
Appendix C: Requirements to fulfil when conducting and reporting new tests for REACH purposes

A. Test methods, GLP requirements and reporting

1. Under Article 13(3) of REACH, all new data generated as a result of this decision must be conducted according to the test methods laid down in a European Commission Regulation or to international test methods recognised by the Commission or ECHA as being appropriate.

2. Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.

3. Under Article 10(a)(vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide on How to report robust study summaries\(^5\).

B. Test material

Before generating new data, you must agree within the joint submission on the chemical composition of the material to be tested (Test Material) which must be relevant for all the registrants of the Substance.

1. Selection of the Test material(s)
   
   The Test Material used to generate the new data must be selected taking into account the following:
   
   - the variation in compositions reported by all members of the joint submission,
   - the boundary composition(s) of the Substance,
   - the impact of each constituent/impurity on the test results for the endpoint to be assessed. For example, if a constituent/impurity of the Substance is known to have an impact on (eco)toxicity, the selected Test Material must contain that constituent/impurity.

2. Information on the Test Material needed in the updated dossier
   
   - You must report the composition of the Test Material selected for each study, under the “Test material information” section, for each respective endpoint study record in IUCLID.
   
   - The reported composition must include all constituents of each Test Material and their concentration values and other parameters relevant for the property to be tested.

This information is needed to assess whether the Test Material is relevant for the Substance and whether it is suitable for use by all members of the joint submission.

Technical instructions on how to report the above is available in the manual on How to prepare registration and PPORD dossiers\(^6\).

---


\(^6\) [https://echa.europa.eu/manuals](https://echa.europa.eu/manuals)
Appendix D: Procedure

In accordance with Article 42(1) of the REACH Regulation, the Agency examined the information submitted by you in consequence of decision of 23 November 2018 ("the original decision"). Agency considered that this information did not meet one or more of the requests contained in that decision. Therefore, a new decision-making process was initiated under Article 41 of the REACH Regulation.

This decision does not prevent ECHA from initiating further compliance checks at a later stage on the registrations present.

ECHA followed the procedure detailed in Articles 50 and 51 of REACH.

ECHA notified you of the draft decision and invited you to provide comments.

ECHA took your comments into account and did not amend the request(s).

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.
Appendix E: List of references - ECHA Guidance\(^7\) and other supporting documents

**Evaluation of available information**
Guidance on information requirements and chemical safety assessment, Chapter R.4 (version 1.1., December 2011), referred to as ECHA Guidance R.4 where relevant.

**QSARs, read-across and grouping**
Guidance on information requirements and chemical safety assessment, Chapter R.6 (version 1.0, May 2008), referred to as ECHA Guidance R.6 where relevant.

**Read-across assessment framework (RAAF, March 2017)\(^8\)**
RAAF - considerations on multiconstituent substances and UVCBs (RAAF UVCB, March 2017)\(^9\)

**Physical-chemical properties**
Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

**Toxicology**
Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

**Environmental toxicology and fate**
Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7b (version 4.0, June 2017), referred to as ECHA Guidance R.7b in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

**PBT assessment**
Guidance on information requirements and chemical safety assessment, Chapter R.11 (version 3.0, June 2017), referred to as ECHA Guidance R.11 in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.16 (version 3.0, February 2016), referred to as ECHA Guidance R.16 in this decision.

**Data sharing**
Guidance on data-sharing (version 3.1, January 2017), referred to as ECHA Guidance on data sharing in this decision.

**OECD Guidance documents\(^{10}\)**


\(^{10}\) [http://www.oecd.org/chemicalsafety/testing/series-testing-assessment-publications-number.htm](http://www.oecd.org/chemicalsafety/testing/series-testing-assessment-publications-number.htm)

Guidance document on transformation/dissolution of metals and metal compounds in aqueous media – No 29, referred to as OECD GD 29.

Guidance Document on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption – No 150, referred to as OECD GD 150.

Guidance Document supporting OECD test guideline 443 on the extended one-generation reproductive toxicity test – No 151, referred to as OECD GD 151.
Appendix F: Addressees of this decision and the corresponding information requirements applicable to them

You must provide the information requested in this decision for all REACH Annexes applicable to you.

<table>
<thead>
<tr>
<th>Registrant Name</th>
<th>Registration number</th>
<th>Highest REACH Annex applicable to you</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Where applicable, the name of a third party representative (TPR) may be displayed in the list of recipients whereas ECHA will send the decision to the actual registrant.